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An increasing trend towards later childbearing has been reported recently in many developed  
countries. Although the incidence of reproductive age women women who have delayed 
pregnancy with cancer is 10%, they may be concerned regarding preservation of ovarian 
function due to advanced fertile age and with the impact of cancer treatment on later fertility. 
Among multiple strategies controlled ovarian stimulation for embryo or oocyte 
cryopreservation is currently the most established method for fertility preservation. It is 
important to choose the appropriate ovulation induction protocol prior to oncologic treatment, 
because most of these patients have only the chance of a single cycle to conceive. Current 
treatment protocols offer a minimal time delay until oncologic treatment is commenced. In 
urgent settings, random-start ovarian stimulation represents a new technique which provides a 
significant advantage by decreasing the total time of the treatment, and because it may be 
started irrespective of the phase of the cycle without compromising oocyte yield and maturity 
before cancer treatment. However, in patients with oestrogen-sensitive cancers stimulation 
protocols using letrozole are currently preferred over tamoxifen regimens, and therefore it 
may be highly advisable to use letrozole with gonadotrophins routinely as a safe, effective 
and novel protocol of ovulation induction. 
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Introduction 
Many countries of the developed world have experienced an increasing trend towards later 
childbearing, commonly between 30 to 44 years of age in recent years and for a variety of 
reasons. In the United States the birth rate for women aged 30-34 years increased from 80.8 
births per 1,000 women in 1990 to 96.5 births  per 1,000 women in 2011. In addition, the rate 
for women aged 35-44 years rose 54% from 1990 to 2011, increasing from 37.2 to 57.5 births 
per 1,000 women [1]. Although about 10% of female cancers occur under the age of 45 years, 
over the past three decades there has been a remarkable improvement in survival rates due to 
advances in cancer diagnoses and therapies at an earlier stage. It was found that from 2002 to 
2012, 83% of women younger than 45 years who were diagnosed with cancer survived [2].  
Because the incidence of premenopausal women with cancer who have delayed 
pregnancy is increasing, they may have concerns regarding the quality of life and preservation 
of ovarian function due to advanced fertile age, particularly with the impact of cancer 
treatment on the outcome of later fertility and pregnancy. Therefore, women of reproductive 
age should have expert counselling and should be given the opportunity to make active 
decisions about preserving fertility. Specialized counselling about loss of reproductive 
function and fertility preservation is associated with more empowered decision-making and 
increased quality of life for survivors. For patients to receive appropriate counseling, it is 
important that they understand the potential increased risk of infertility and early menopause 
beyond that of acute ovarian failure [3,4]. Fertility preservation issues should be addressed 
within a multidiciplinary environment, including oncologists and fertility specialists [5].  
The treatment for most of the cancer types in reproductive age-women includes 
removal of the reproductive organs or cytotoxic treatment that may partially or definitively  
affect reproductive function. One of the most devastating consequences of cytotoxic treatment 
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with chemotherapy and radiation in the young female population is ovarian damage, resulting 
in diminished fertility potential [6]. The impact of chemotherapy on a woman's fertility 
depends on her age and the types and doses of the drugs used. Alkylating agents have the 
biggest negative impact on ovarian function. The effects of external radiation therapy and 
brachytherapy on the ovaries depend on three factors: the patient's age, the dose delivered to 
the ovaries, and concurrent use of chemotherapy. Female patients who receive high-dose 
abdominal and/or pelvic irradiation or chemotherapy based on alkylating agents are at highest 
risk of developing ovarian failure [7]. In addition, women treated with abdomino-pelvic 
radiation have an increased rate of uterine dysfunction leading to miscarriage, preterm labour, 
low birth weight, and placental abnormalities [8].  
The field of fertility preservation has been developed in order to overcome the adverse 
effects of cytotoxic cancer treatments on gonadal function. The strategy of fertility 
preservation depends on the patient's age, and the time frame before the initiation of 
gonadotoxic treatments. Multiple strategies have emerged aimed at preserving fertility in 
women with different types of malignancies including embryo and oocyte cryopreservation, 
cortical and whole ovary cryopreservation, ovarian transplantation, ovarian transposition, and 
administration of GnRH agonists during chemotherapy. Embryo or oocyte cryopreservation 
after controlled ovarian hyperstimulation is currently the most established technique of 
fertility preservation, but ovarian tissue freezing may also be offered despite the fact that it is 
still considered experimental. More recently, in vitro maturation of the oocyte has been 
proposed in the strategy of fertility preservation since it does not require ovarian stimulation 
and can be performed at any time of the menstrual cycle. Therefore, in vitro maturation 
represents an attractive approach for urgent fertility preservation and/or in patients suffering 
from oestrogen-sensitive cancers [9]. Currently, sperm and embryo cryopreservation and 
oocyte cryopreservation are the only techniques endorsed by the American Society of Clinical 
 5
Oncology widely available as standard practice. Other fertility preservation methods should 
be considered investigational and should be performed by care providers with the necessary 
expertise [10]. 
 
Strategies for ovarian stimulation 
Controlled ovarian stimulation for mature oocyte and embryo cryopreservation is the 
preferred method for fertility preservation in cancer patients due to its higher success rates 
compared with other, more experimental techniques. The reports about the response of cancer 
patients to ovarian stimulation protocols widely vary, from some reporting no significant 
change and others demonstrating worse ovarian response compared with age-matched healthy 
women. It appears that in women with malignancy undergoing in vitro fertilization (IVF) 
before chemotherapy or radiotherapy, ovarian reserve, response to gonadotrophins, oocytes 
retrieved, and oocyte maturity remain unaltered by the neoplastic process [11]. However, the 
results of a recent meta-analysis indicate that the number of retrieved oocytes was statistically 
significantly lower compared with age-matched healthy IVF patients [12]. Moreover, ovarian 
reserve assesed with anti-mullerian hormone (AMH) and antral follicle count (AFC) were 
found to be significantly lower in patients with malignancy before gonadotoxic therapy, 
which  may be explained by either accelerated follicle loss or a defect in recruitment of antral 
follicles due to disease state [13, 14]. Therefore, maximizing the number of embryos and 
oocytes during a fertility preservation preservation cycle without causing ovarian 
hyperstimulation syndrome is extremely important, because most women have only the 
opportunity to undergo a single cycle of IVF owing to time constraints before starting 
oncologic treatment.  Determination of the ovarian stimulation protocol and gonadotrophin 
dose for oocyte/embryo cryopreservation requires an individualised assesment. The choice of 
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the specific ovarian stimulation strategy is usually determined by the time available until the 
initiation of chemotherapy or radiotherapy [15].   
Traditional ovarian stimulation protocols for IVF required awaiting spontaneous 
menses before 9–14 days of ovarian stimulation with exogenous gonadotrophins preceded by 
ovarian suppression with gonadotrophin releasing hormone (GnRH) agonists to prevent 
premature ovulation for approximately 2 weeks. Therefore, preserving oocytes or embryos 
has required a delay in cancer treatment of more than a month to complete the IVF cycle [15].  
Conventional-start stimulation protocols that include the introduction of GnRH 
antagonists have significantly decreased the interval from patient presentation to oocyte or 
embryo cryopreservation. Currently, the majority of patients are treated with a GnRH 
antagonist-based regimen, which usually enables the shortest time to initiation of 
chemotherapy or radiotherapy. In contrast to GnRH agonists, GnRH antagonists immediately 
suppress pituitary release of follicle stimulating hormone (FSH) and luteinizing hormone 
(LH) and do not require the 10–14 days of administration prior to gonadotrophin initiation. 
Conventional-start ovarian stimulation can be started following spontaneous menses with 
gonadotrophins and GnRH antagonists initiated in the early follicular phase or with menses 
following luteolysis induced by GnRH antagonist during the preceding luteal phase. In the 
first approach GnRH antagonists are initiated usually at day six of the cycle when the size of 
the lead follicle reaches 12-13 mm during gonadotrophin stimulation, which begins on day 2-
3 of the cycle. Although this approach still requires awaiting spontaneous menses prior to 
initiating gonadotrophins, it decreases the interval to oocyte retrieval compared to traditional 
IVF stimulation protocols. However, if the use of a GnRH antagonist (e.g. single dose of 3 mg 
cetrorelix subcutaneously) is initiated during the midluteal phase, menses usually ensues a 
few days later following corpus luteum breakdown. Administration of GnRH antagonists in 
the luteal phase results in the quicker initiation of ovarian stimulation and restart of GnRH 
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antagonist in a standard fashion, reducing delays for cancer treatment and improving clinical 
outcome in poor responders. Nevertheless, despite these effects adhering to the conventional-
start antagonist protocols may result in either significant delay of cancer treatments or 
forgoing of fertility preservation due to time constraints  [15,16].  
 Random-start ovarian stimulation protocol is emerging as a new technique for the 
purpose of fertility preservation for cases in which waiting for the next menstrual period to 
start with ovulation induction is advisable due to the urgency of the cancer treatment. 
Controlled ovarian stimulation has been proposed to be initiated in the late follicular phase or 
luteal phase following spontaneous LH surge or after ovulation induction with human 
chorionic gonadotrophin (hCG) or a GnRH agonist [15]. If the cancer patient presented in the 
late follicular phase, ovarian stimulation may be started without a GnRH antagonist if the 
follicle cohort following the lead follicle  is < 12 mm and continues  to be < 12 mm before 
spontaneous LH surge. After the LH surge, a GnRH antagonist my be started later in the cycle 
after the secondary follicle cohort reaches 12 mm to prevent premature secondary LH surge. 
Alternatively, ovulation may be induced with hCG or a GnRH agonist  and ovarian 
stimulation  can start in 2-3 days in the luteal phase. However, if the cancer patient is in the 
luteal phase, GnRH antagonists may be initiated similarly to conventional ovarian stimulation 
later in the cycle to down-regulate LH with proceeding luteolysis, and follicular stimulation 
with recombinant FSH may be started simultaneously. Both of the random-start ovarian 
stimulation protocols are as effective as conventional-start regimens in the early follicular 
phase. In addition, random-start ovarian hyperstimulation  provides a significant advantage by 
decreasing the total time for the IVF cycle, and because it may be started irrespective of the 
phase of the cycle for the purpose of fertility preservation without compromising oocyte yield 
and maturity before cancer treatment [17, 18].   
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Oestrogen-sensitive cancers       
The supraphysiologic levels of oestrogens associated with ovarian stimulation with 
gonadotrophins may promote the growth of oestrogen-sensitive tumours and therefore in the 
past elevated oestrogen levels have precluded the use of assisted reproductive technologies in 
the presence of breast cancer [19]. Currently, potentially safer and alternative stimulation 
protocols have been used for fertility preservation for oestrogen–sensitive cancer patients, 
including natural cycle IVF, tamoxifen and aromatase inhibitors to induce lower levels of 
estradiol [20].   
Natural cycle IVF has been offered traditionally for women with breast cancer in order 
to avoid the possible risks of ovarian stimulation, but it resulted in an extremely low gamete 
yield. Because the technique of natural cycle IVF is accompanied with a high rate of 
cancellation and gives the smallest number of oocytes or embryos per cycle, it is not 
recommended when a gonadotoxic therapy is approaching and when the patient is without 
another chance of IVF treatment [15].  
Tamoxifen, a nonsteroidal compound related to clomiphene, expresses its action by 
competitive antagonism at its receptor site. In some organs such as the uterus and bones 
tamoxifen has agonist actions on oestrogen receptors, and antagonist effects on breast cancer 
cells, thus inhibiting the proliferative effect of oestrogens. Tamoxifen has been accepted as 
the first-line drug in hormonal prevention and treatment of receptor-positive breast cancer 
tissue. In addition to its negative effects in the breast it also has an antagonist action in the 
oestrogen receptors in the central nervous system which interferes with the negative feedback 
of the oestrogen, leading to an increase of GnRH and gonadotrophins. Tamoxifen can be used 
for ovulation induction alone starting on day 2-5 of the menstrual cycle in doses 20-60 mg/d, 
or in combination with gonadotrophins similar to the use of clomiphene [20]. Although 
oestrogen levels during ovarian stimulation with tamoxifen are not altered, its use in 
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oestrogen receptor-positive breast cancer patients is desirable, due to its antioestrogenic  
effect  on breast tissue. Ovulation induction with tamoxifen for fertility preservation in cancer 
patients has been shown to increase mature oocyte and embryo yield compared with natural 
cycle IVF (1.6 vs.0.7 and 1.6 vs. 0.6 respectively), reducing cycle cancellations. Whereas all 
patients had at least one embryo in the tamoxifen group, 40% of cycles did not result in 
embryo development in the natural cycle IVF group [21]. Moreover, the combination  of low-
dose FSH with tamoxifen (60 mg/d) further increased the number of cryopreserved oocytes 
and embryos compared with ovulation induction with tamoxifen alone (5.1 vs.1.5 and 3.8 
vs.1.3 respectively) [22].  
Aromatase inhibitors significantly reduce plasma oestrogen levels by competitively 
suppressing the activity of the aromatase enzyme. Because greater proliferative capacity of 
endocrine-responsive breast cancer is often due to increased local aromatase activity and 
oestrogen production, letrozol, a third-generation aromatase inhibitor, is important in adjuvant 
treatment reducing the risk of recurrent disease. In contrast to tamoxifen, which inhibits the 
activity of oestrogen by competitively binding to the oestrogen receptor, aromatase inhibitors 
block the conversion of androgens to estrogens and reduce oestrogen levels in tissue and 
plasma [23]. Oestrogen receptor-positive breast cancer patients undergoing controlled ovarian 
hyperstimulation for embryo or oocyte cryopreservation should be induced by the method that 
leads to the least increase in estradiol  levels. In addition to local inhibitory effects on 
aromatase activity, aromatase inhibitors release the hypothalamic-pituitary axis from 
estrogenic negative feedback, increase the secretion of gonadotrophins, stimulate follicle 
growth, and thereby can be used in ovulation induction. In patients with oestrogen–sensitive 
cancers the main advantage of adding daily letrozol to gonadotrophins in ovarian stimulation 
protocols is decreasing plasma estradiol levels and bringing them closer to those observed in 
natural cycles, or about 50% of the results with clomifene. Comparing the efficacy of the 
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letrozol with gonadotrophin protocol in breast cancer patients before chemotherapy and 
standard IVF in noncancer women, the former started to receive letrozole (5 mg/d) from day 2 
or 3 of the cycle and FSH (150 – 300 IU) two days later. All medications were discontinued 
on the day of the hCG trigger, and letrozole was reinitiated after oocyte retrieval and 
continued until oestrogen levels fell to < 50 pg/ml. Whereas letrozole and FSH stimulation 
resulted in significantly lower peak estradiol levels (483.4 +/- 278.9 vs. 1464.6 +/- 644.9 
pg/ml) and a 44% reduction in gonadotrophin requirement, in comparison with controls, the 
length of stimulation, number of embryos obtained, and fertilization rates were similar. 
Therefore, ovarian stimulation with letrozole and FSH appears to be a cost-effective 
alternative with reduced oestrogen exposure for fertility preservation in breast cancer patients, 
compared with standard IVF. In addition, patients should be referred promptly so that they 
may undergo embryo or oocyte cryopreservation without a delay in chemotherapy [24]. 
However, these findings have not been confirmed recently because patients who received 
letrozole required higher gonadotrophin doses and produced more immature oocytes, 
suggesting that the response to ovarian stimulation may be impaired in patients with 
hormone-sensitive cancers receiving letrozole [25]. Stimulation protocols using letrozole are 
currently preferred over tamoxifen protocols because treatment with tamoxifen alone and 
tamoxifen 60 mg/d or letrozole 5 mg in combination with FSH  results in a greater number of 
follicles (2 +/- 0.3 vs. 6 +/- 1 and 7.8 +/- 0.9 respectively), mature oocytes (1.5 +/- 0.3 vs. 5.1 
+/- 1.1 and 8.5 +/- 1.6 respectively), and embryos (1.3 +/- 0.2 vs. 3.8 +/- 0.8 and 5.3 +/- 0.8, 
respectively). In addition, peak estradiol levels were lower with letrozole in combination with 
FSH and tamoxifen compared with tamoxifen and FSH [22]. Moreover, it appears that the 
safety of fertility preservation by ovarian stimulation with letrozole and gonadotrophins in 
patients with breast cancer is not compromised because it is unlikely to cause a substantially 
increased risk of recurrence [26].  In addition, the use of letrozole and gonadotrophins is also 
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associated with beneficial effects showing lower estradiol levels compared with standard 
stimulation cycles in young women with endometrial carcinoma  [27]. Although letrozole has 
been shown to be teratogenic in rodents when exposure occurs during organogenesis, there is 
no clinical evidence that letrozole use is associated with increased birth defects, nor is this 
biologically plausible in the setting of ovulation induction. [28]. Therefore, in an effort to 
mitigate the potential effects of elevated oestrogen levels during ovarian stimulation for 
fertility preservation prior to gonadotoxic treatment of oestrogen-sensitive cancer patients, it 
may be highly advisable to use letrozole routinely as a safe, effective and novel protocol for 
ovulation induction [15, 19]. However, anastrozole another third-generation aromatase 
inhibitor has a minimal suppressive effect on rising estradiol levels during ovarian 
stimulation, even at five times the comparable dose of letrozole. As a result, breast cancer 
patients who underwent ovarian stimulation with anastrozole, despite an increased dose of the 
drug  to 10 mg,  had a significantly higher exposure to estradiol than those who were 
stimulated with letrozole [29].  Therefore, the use of anastrozole is not recommended in 
fertility preservation cycles of oestrogen-sensitive cancer patients prior to chemotherapy [15].  
 
Complications of ovarian stimulation 
Ovarian hyperstimulation syndrome the most serious complication of ovulation 
induction, may appear during a fertility preservation cycle in cancer patients after obtaining a 
sufficient number of oocytes and embryos to maximize the chance of a successful pregnancy 
due to time constraints before oncologic treatment. Therefore, it is important to choose the 
appropriate ovulation induction protocol in patients with malignancy because most of these 
patients have only the oppurtunity of a single cycle to conceive. Otherwise, the risk of ovarian 
hyperstimulation syndrome may result in a delay or interference of the programmed cancer 
treatment [15]. It is that known that hCG induces the final oocyte maturation and contributes 
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as the main trigger to ovarian hyperstimulation syndrome. In women at risk for the syndrome 
GnRH agonists can be used as an alternative to hCG in GnRH antagonist-based regimens, 
which reduce the risk owing to the short half-life of agonist-induced endogenous LH surge. 
Accordingly, a significantly lower rate of moderate/severe ovarian hyperstimulation 
syndrome in the GnRH agonist group has been found compared with patients  receiving hCG 
(3.7  vs. 21.3%) [30]. However, trigger failures that have been observed with GnRH agonists 
at doses 1 mg to 4 mg may be explained by partial binding to its receptors due to competition 
with GnRH antagonists, resulting in a limited LH surge. It appears that with hCG 
supplementation (< 1500 IU) at the time of trigger there will be fewer failures. However, in 
women at risk for the syndrome in the case of a GnRH trigger failure determined on the next 
morning by low post-trigger LH (< 12 IU), an hCG (2,500-5,000 IU) trigger can be used on 
the same day. In the case that oocyte aspiration does not result in a retrieval of a couple of 
mature-sized follicles, the oocyte retrieval should be stopped and oocyte maturation should be 
again triggered by the same dose of hCG  [15].   
 Patients with cancer undergoing ovarian stimulation with the exogenous 
administration of high dose gonadotrophin for ovulation induction are at risk of 
thromboembolic disease due to a hypercoagulable state associated with haemostasis and 
thrombophilias.induced by their malignancy and hyperestrogenism. Therefore, the safety and 
efficacy of anticoagulation by dose-adjusted heparinisation is recommended as the first-line 
treatment of choice [31]. In addition, during induction of ovulation in patients at risk for 
thrombosis, the introduction of low molecular weight heparin as a cycle protective treatment 
was not associated with any medical complication [32]. Although there are no guidelines for 
anticoagulation during ovulation induction prophylactic low molecular weight heparin may be 
stopped 24 hours before the oocyte retrieval and reinitiated 12 hours after the retrieval 
continuously until oestrogen returns to its baseline level. An alternative strategy of 
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anticoagulant therapy is the use of letrozole at 2.5 or 5 mg/d during ovarian stimulation to 
decrease oestrogen concentrations similar to those in natural cycles [15]. 
   
 
Conclusions 
It is important to choose the appropriate controlled ovarian stimulation protocol for 
oocyte/embryo cryopreservation in patients with malignancy because most of these patients 
have only the chance of single cycle chance to conceive prior to cancer treatment. The 
influence of ovarian hyperstimulation syndrome may be a serious complication in cancer 
patients because it may result in a delay and interference of  planned cancer treatment. 
Current treatment protocols offer a minimal time delay until malignancy treatment is 
commenced. Emergency IVF is a promising approach for preserving fertility in cancer 
patients, because random-start ovarian stimulation protocol represents a new technique which 
provides a significant advantage by decreasing the total time of the IVF cycle. In addition, it 
may be started irrespective of the phase of the cycle for the purpose of fertility preservation 
without compromising oocyte yield and maturity before cancer treatment. However, in 
patients with oestrogen-sensitive cancers stimulation protocols using letrozole are currently 
preferred over tamoxifen regimens, because treatment with letrozole in combination with 
gonadotrophins results in a greater number of follicles, oocytes and embryos. Therefore, it 
may be highly recommended to use letrozole with gonadotrophins routinely as a safe, 
effective and novel protocol of ovulation induction for oocyte/embryo cryopreservation in 
cancer patients prior to oncologic treatment. Despite the efficacy of these newly developed 
ovarian stimulation protocols in order to obtain the maximal number of oocytes and embryos 
for fertility preservation, future studies are required to estimate their final implantation and 
conception success rates.  
 14
 
Declaration of Interest: The authors report no declarations of interest. 
 
 
 
References 
 
1. Hamilton BE, Martin JA, Ventura SJ.Births: preliminary datafor 2011. In: National 
vital statistics reports web release, vol.61, no.5 Hyattsville, MD: National Center for 
Health Statistics; 2012. 
2. Howlader N, Noone AM, Krapch M, Neyman N, Aminou R, Waldron W, et al. 
(eds.). SEER cancer statistics review, 1975-2009 (vintage 2009 populations). 
Bethasda, MD. National Cancer Institute. Available at: 
http://seer.cancer.gov/csr/1975_2009_pops09/. Accessed December 16, 2012. 
3. Letourneau JM, Ebbel EE, Katz PP, Katz A, Ai WZ, Chien AJ, et al. Pretreatment 
fertility counseling and fertility preservation improve quality of life in reproductive 
age women with cancer. Cancer 2012;118:1710-17.  
4. Letourneau JM, Ebbel EE, Katz PP, Oktay KH, McCulloch CE, Ai WZ, et al.  Acute 
ovarian failure underestimates age-specific reproductive impairment for young 
women undergoing chemotherapy for cancer. Cancer 2012;118:1933-9.  
5. Wyns C. Fertility preservation: current prospects and future challenges. Gynecol 
Endocrinol 2013; 29: 403-7.  
6. Meirow D, Biederman H, Andersom RA, Walace WH. Toxicity of chemotherapy 
and radiation on female reproduction. Clin Obstet Gynecol 2010; 53:727-9.  
 15
7. Morice P, Uzan C, Gouy S, Pautier P, Lhomme C, Balleyguier C, et al. [Effects of 
radiotherapy (external and/or internal) and chemotherapy on female fertility]. Bull 
Acad Natl Med. 2010;194:481-92.  
8. Wo JY, Shipley WU, Dahl DM, Coen JJ, Heney NM, Kaufman DS, et al. Impact of 
radiotherapy on fertility, pregnancy, and neonatal outcomes in female cancer 
patients. BJU Int 2009;104:179-83.  
9. Grynberg M, Poulain M, Le Parco S, Sebag-Peyrelevade S, Frydman N, Benachi A. 
[How to preserve female fertility before cancer treatments?]. Rev Prat 2013;63:314-
18.    
10. Loren AW, Mangu PB, Beck LN, Brennan L, Magdalinski AJ, Partridge AH, et al. 
Fertility Preservation for Patients With Cancer: American Society of Clinical 
Oncology Clinical Practice Guideline Update. J Clin Oncol 2013 May 28 
11. Das M, Shehata F, Moria A, Holzer H, Son WY, Tulandi T. Ovarian reserve, 
response to gonadotropins, and oocyte maturity in women with malignancy. Fertil 
Steril 2011;96:122-5.  
12. Friedler S, Koc O, Gidoni Y, Raziel A, Ron-El R. Ovarian response to stimulation 
for fertility preservation in women with malignant disease: a systematic review and 
meta-analysis. Fertil Steril 2012;97:125-33.  
13. Lawrenz B, Fehm T, von Wolff M, Soekler M, Huebner S, Henes J, et al. Reduced 
pretreatment ovarian reserve in premenopausal female patients with Hodgkin 
lymphoma or non-Hodgkin-lymphoma--evaluation by using antimüllerian hormone 
and retrieved oocytes. Fertil Steril 2012; 98:141-4. 
14. Ebbel E, Katz A, Kao CN, Cedars MI, Rosen MP. Reproductive aged women with 
cancer have a lower antral follicle count than expected. Fertil Steril 2011; 96: S 199-
200. 
 16
15. Cakmak H, Rosen MP. Ovarian stimulation in cancer patients. Fertil Steril 
2013;99:1476-84.  
16. Humaidan P, Bungum L, Bungum M, Hald F, Agerholm I, Blaabjerg J, et al. 
Reproductive outcome using a GnRH antagonist (cetrorelix) for luteolysis and 
follicular synchronization in poor responder IVF/ICSI patients treated with a flexible 
GnRH antagonist protocol. Reprod Biomed Online 2005;11:679-84. 
17. Cakmak H, Zamah AM, Katz A, Cedars MI, Rosen MP. Effective method for 
emergency fertility preservation: random-start controlled ovarian hyperstimulation. 
Fertil Steril 2012; 98: S 170-8.  
18. von Wolff M, Thaler CJ, Frambach T, Zeeb C, Lawrenz B, Popovici RM, et al. 
Ovarian stimulation to cryopreserve fertilized oocytes in cancer patients can be 
started in the luteal phase. Fertil Steril 2009;92:1360-5.  
19. Reddy J, Oktay K. Ovarian stimulation and fertility preservation with the use of 
aromatase inhibitors in women with breast cancer. Fertil Steril 2012;98:1363-9.  
20. Rodriguez-Walberg  KA, Oktay K.  Fertility preservation in women with breast 
cancer. Clin Obstet Gynecol 2010; 53: 753-62.  
21. Oktay K, Buyuk E, Davis O, Yermakova I, Veeck L, Rosenwacks Z. Fertility 
preservation in breast cancer patients: IVF and embryo cryopreservation after 
ovarian stimulation with tamoxifen. Hum Reprod 2003; 18: 90-5.  
22. Oktay K, Buyuk E, Libertella L, Akar M,  Rosenwaks Z. Fertility preservation in 
breast cancer patients: a prospective controlled comparison of ovarian stimulation 
with tamoxifen and letrozole for embryo cryopreservation. J Clin Oncol 2005; 23: 
4347-53. 
 17
23. Thurlimann B, Keshaviah A, Coates AS, Mouridsen H, Mauriac L, Forbes JF, et al. 
A comparison of letrozole and tamoxifen in postmenopausal women with early 
breast cancer. N Engl J Med 2005;353:2747–57. 
24. Oktay K, Hourvitz A, Oktem O, Safro B, Cil A, Bang H. Letrozole reduces estrogen 
and gonadotropin exposure in women with breast cancer undergoing ovarian 
stimulation before chemotherapy. J Clin Endocrinol Metab 2006;91:3885-90. 
25. Johnson LN, Dillon KE, Sammel MD, Efymow ML, Mainigi MA, Dokras A et al. 
Response to ovarian stimulation in patients facing gonadotoxic therapy. Reprod 
Biomed Online 2013;26:337-44.  
26. Azemi AA, Constantini-Ferrando M, Oktay K. Safety of fertility preservation by 
ovarian stimulation with letrozole and gonadotropins in patients with breast cancer: 
a prospective controlled study. J Clin Oncol 2008; 26:2630-5.  
27. Azim A, Oktay K. Letrozole for ovulation induction and fertility preservation by 
embryo cryopreservation in young women with endometrial carcinoma. J Clin 
Oncol 2008; 26: 2630-5. 
28. Tiboni GM.Aromatase inhibitors and teratogenesis. Fertil Steril 2004; 81:1158–9. 
29. Azim AA, Constantini-Ferrando M, Lostrito K, Oktay K. Relative potencies of 
anastrozole and letrozole to suppress estradiol in breast cancer patients undergoing 
ovarian stimulation before in vitro fertilization. J Clin Endocrinol Metabol 2007; 92: 
2197-200.  
30. Engmann L, DiLuigi A, Schmidt D, Nulsen J, Maier D, Benadiva C. The use of 
gonadotropin-releasing hormone (GnRH) agonist to induce oocyte maturation after 
cotreatment with GnRH antagonist in high-risk patients undergoing in vitro 
fertilization prevents the risk of ovarian hyperstimulation syndrome: a prospective 
randomized controlled study. Fertil Steril 2008;89:84-91. 
 18
31. Ou YC, Kao YL, Lai SL, Kung FT, Huang FJ, Chang SJ et al. Thromboembolism 
after ovarian stimulation: successful management of a woman with superior sagittal 
sinus thrombosis after IVF and embryo transfer: case report. Hum Reprod 2003; 18: 
2375-81.  
32. Yinon Y, Pauzner R, Dulitzky M, Elizur SE, Dor J, Shulman A. Safety of IVF under 
anticoagulant therapy in patients at risk for thrombo-embolic events. Reprod Biomed 
Online 2006; 12: 354-8. 
 
 
 
 
 
 
 
 
 
